Darunavir and ritonavir pharmacokinetics

1 – 3 Once-daily darunavir is approved for use in combination with low-dose ritonavir (darunavir/ritonavir) and other antiretrovirals for HIV-1-infected, treatment-naive adults and adolescents at a dose of 800/100 mg. Darunavir inhibits and is primarily metabolized by cytochrome P450 3A (CYP3A) isoenzymes and is co-administered with low-dose ritonavir (darunavir/r); ritonavir is an Physiological changes during pregnancy can affect pharmacokinetics

2024-03-28
    Anastrozole 1 mg picture
  1. 5%) and, to a lesser extent, in urine (13
  2. Darunavir reaches peak serum concentrations 2
  3. 5 ± 1
  4. d
  5. g
  6. However, during
  7. 9 and 5
  8. We successfully approximated the increase in darunavir exposure
  9. i
  10. In vitro, ritonavir is a potent inhibitor of CYP3A
  11. 8% was unchanged parent drug
  12. i